Stockscreener 앱 받기
0.6451
5.41%
-0.0369
시간 외 거래:
.61
-0.0351
-5.44%
전일 마감가:
$0.682
열려 있는:
$0.703
하루 거래량:
38,523
Relative Volume:
0.02
시가총액:
$937.55K
수익:
$2,000
순이익/손실:
$-12.72M
주가수익비율:
-0.00898
EPS:
-71.8121
순현금흐름:
$-3.91M
1주 성능:
-24.77%
1개월 성능:
-52.91%
6개월 성능:
-83.75%
1년 성능:
+0.00%
1일 변동 폭
$0.6116
$0.71
1주일 범위
$0.5994
$0.873
52주 변동 폭
$0.5994
$23.80
Nexentis Technologies Inc Stock (NXTS) Company Profile
명칭
Nexentis Technologies Inc
전화
972544561349
주소
156 FIFTH AVENUE 10TH FLOOR, NEW YORK
Compare NXTS vs NTR, CF, CTVA, ICL, MOS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXTS
Nexentis Technologies Inc
|
0.6451 | 937.55K | 2,000 | -12.72M | -3.91M | -71.81 |
NTR
Nutrien Ltd
|
71.26 | 34.01B | 27.83B | 2.42B | 2.21B | 4.9113 |
CF
Cf Industries Holdings Inc
|
120.85 | 18.29B | 7.41B | 2.12B | 1.62B | 11.13 |
CTVA
Corteva Inc
|
12.88 | 8.59B | 17.89B | 1.26B | 2.05B | 1.7029 |
ICL
Icl Group Ltd
|
4.97 | 6.41B | 7.41B | 314.00M | 220.88M | 0.202 |
MOS
Mosaic Company
|
18.82 | 5.98B | 12.43B | 70.90M | -489.30M | 0.1275 |
Nexentis Technologies Inc 주식(NXTS)의 최신 뉴스
NXTS Stock Slides As Charts And Cash Flow Flash Caution - Timothy Sykes
NXTS Stock Compresses As Traders Study Key Levels - StocksToTrade
NXTS Stock Tests Volatility As Cash Cushion Buys Time - StocksToTrade
Nexentis Amends All Outstanding Warrants to Equity Classification for Nasdaq Compliance - Minichart
Warrant amendments at Nexentis (NXTS) add no shares upon exercise and do not extend their terms. - Stock Titan
NXTS Forecast — Price Target — Prediction for 2027 - TradingView
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board - GlobeNewswire Inc.
Nexentis Technologies Inc. (NXTS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Nexentis Technologies Inc. (NXTS) stock price, news, quote and history - Yahoo Finance UK
Nexentis Technologies Faces Nasdaq Compliance and Delisting Risk - The Globe and Mail
Nexentis Faces Nasdaq Delisting Over Equity Shortfall - minichart.com.sg
Nexentis Technologies Faces Nasdaq Compliance and Delisting Risk - TipRanks
Nexentis Technologies Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
NXTS - Finviz
Nexentis Technologies Inc. (NASDAQ: NXTS) Share Price, NXTS Stock News, NXTS Share Price & Updates - Kalkine
Nexentis Technologies Inc. (NXTS) Rises 5.98% to $1.95, Approaching Key Resistance at $2.05Hedge Fund Favorites - Vinanet
Nexentis Technologies (NXTS) flags going concern after $17.7M loss and $6.3M impairment - Stock Titan
Nexentis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nexentis Technologies Inc. (NXTS) Rises 5.98% to $1.95, Approaching Key Resistance at $2.05Hedge Fund Favorites - vinanet.vn
Nexentis Technologies (NASDAQ: NXTS) changes auditors after prior going concern note - Stock Titan
Nexentis Technologies (NXTS) Gains 4% as Bullish Momentum Builds Toward Key $2.03 ResistanceInstitutional Volume - vinanet.vn
NXTS Q2 2025 Earnings: Loss of $0.18 Per Share Reported as Stock Climbs 10.32%Analyst Earnings Estimate - vinanet.vn
NXTS Q2 2025 Earnings: Reported Loss of -$0.18 Per Share, Yet Shares Jump 10.32%Financial Health Score - vinanet.vn
Nexentis subsidiary selects candidate for drug discovery program By Investing.com - Investing.com Canada
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign - globenewswire.com
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign - The Manila Times
Nexentis Technologies Inc. (NXTS) Q2 2025 Earnings: Loss and Stock Decline Reflect Ongoing ChallengesDividend Cut Risk - dars.gov.et
Nexentis Technologies Inc. (NXTS) Q2 2025 Earnings: Loss and Stock Decline Reflect Ongoing Challenges - dars.gov.et
Nexentis Technologies Inc. (NXTS) Q2 2025 Earnings: Loss and Stock Decline Reflect Ongoing Challenges - dars.gov.et
Nexentis Technologies Inc. Revenue Breakdown – NASDAQ:NXTS - TradingView
Nexentis Technologies (NXTS) Drops 7%: Key Support Level in FocusStraddle Setup - dars.gov.et
NXTS Q2 2025 Earnings: Wider-than-expected loss drives shares down 7.86%Earnings Season Outlook - vinanet.vn
Nexentis Technologies Inc. SEC Filing (Jul 20, 2026) - Stock Titan
NXTS Q2 2025 Earnings: Reported Loss of $0.18 per Share Amid Market SelloffAnalyst Drop Coverage - dars.gov.et
NXTS Q2 2025 Earnings: Reported Loss of $0.18 per Share Amid Market SelloffDownward Estimate Revision - vinanet.vn
Nexentis Technologies soars 156% before falling 46% after hours — here’s why NXTS stock is trending - MSN
Nexentis Technologies Inc. SEC Filing (Jul 16, 2026) - Stock Titan
Eun Young Lee holds 3.23% of Nexentis Technologies Inc. (NXTS) - Stock Titan
NXTS Q2 2025 Earnings: Wider-Than-Expected Loss Sends Shares LowerMargin Compression Risk - vinanet.vn
Nexentis Technologies files prospectus for 2.573M shares - scanx.trade
Nexentis Technologies registers to sell 2.57M shares of common stock for holders - TipRanks
Nexentis Technologies (NASDAQ: NXTS) refreshes $100M shelf and details MitoCareX deal - Stock Titan
Nexentis Technologies (NASDAQ: NXTS) registers 2.57M warrant shares for resale - Stock Titan
Nexentis Technologies Q2 2025 Earnings: Loss of -$0.18 Per Share Sends Stock Down 14.56%Earnings Power Value - vinanet.vn
Nexentis Technologies (NXTS) Slides 4.5% as Selling Pressure Tests Key Support at $3.46Double EMA - dars.gov.et
NXTS Q2 2025 Earnings: Net Loss of $0.18 Per Share as Stock Slips 3.6%Earnings Quality Score - dars.gov.et
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative - The Manila Times
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter - GlobeNewswire
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative - Barchart.com
NXTSNexentis Technologies Inc Earnings - Finviz
Nexentis Technologies Inc (NXTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
32.54%
6.26%
자본화:
|
볼륨(24시간):